In PNAS, there's no shortage of clinically oriented research. This paper from senior author Jeremy Nicholson and team use pharmacometabonomics to identify metabolic interactions in humans that depend on their microbiome; they urge an assessment of these microbial communities as "an integral part of pharmaceutical development and of personalized health care." Ian Wilson offers a commentary.